2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, Brander D, Cortese M, Cripe L, Davis R, Eradat H, Fakhri B, Fletcher C, Gaballa S, Hamid M, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps T, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens D, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach J, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 175-204. PMID: 38626800, DOI: 10.6004/jnccn.2024.0018.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaPredictor of improved survivalUndetectable minimal residual diseaseImmunoglobulin heavy chain variable region mutational statusMinimal residual diseaseManagement of patientsSelection of treatmentRelapsed/refractory CLL/SLLLymphocytic lymphomaResidual diseaseCombination regimensTP53 mutationsMutation statusPerformance statusLymphocytic leukemiaNCCN GuidelinesPatient agePrognostic implicationsToxicity profileDisease stageComorbid conditionsPatientsCLL/SLLCytogenetic variability
2018
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M, Downs T, Efstathiou J, Friedlander T, Greenberg R, Guru K, Hahn N, Herr H, Hoimes C, Inman B, Jimbo M, Kader A, Lele S, Meeks J, Michalski J, Montgomery J, Pagliaro L, Pal S, Patterson A, Petrylak D, Plimack E, Pohar K, Porter M, Preston M, Sexton W, Siefker-Radtke A, Tward J, Wile G, Johnson-Chilla A, Dwyer M, Gurski L. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 1041-1053. PMID: 30181416, DOI: 10.6004/jnccn.2018.0072.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAftercareBCG VaccineChemotherapy, AdjuvantCystectomyHumansLymphatic MetastasisMedical OncologyNeoadjuvant TherapyNeoplasm StagingOrgan Sparing TreatmentsPatient SelectionQuality of LifeRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSocieties, MedicalTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsBladder cancerTreatment of muscle-invasive bladder cancerImmune checkpoint inhibitor therapyMuscle-invasive bladder cancerNCCN Clinical Practice GuidelinesFollow-up of patientsAJCC Cancer Staging ManualCheckpoint inhibitor therapyCancer Staging ManualNCCN Guidelines InsightsClinical practice guidelinesMetastatic diseaseInhibitor therapyStaging ManualTreatment optionsFollow-upCancerBladderPractice guidelinesPatientsNCCNTreatmentAJCCTherapyGuidelinesNCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
Horwitz S, Ansell S, Ai W, Barnes J, Barta S, Choi M, Clemens M, Dogan A, Greer J, Halwani A, Haverkos B, Hoppe R, Jacobsen E, Jagadeesh D, Kim Y, Lunning M, Mehta A, Mehta-Shah N, Oki Y, Olsen E, Pro B, Rajguru S, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer M, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 123-135. PMID: 29439173, DOI: 10.6004/jnccn.2018.0007.Peer-Reviewed Original ResearchConceptsExtranodal NK/T-cell lymphomaNK/T-cell lymphomaNatural killer (NK)/T-cell lymphomaSubtype of non-Hodgkin lymphomaNon-Hodgkin's lymphomaT-cell lymphomaNCCN Guidelines InsightsUpper aerodigestive tractManagement of patientsNasal typeNK/T-cellRare malignancyStandard therapyNCCN GuidelinesAerodigestive tractT cellsLymphomaRandomized trialsPatientsNCCNMalignancyRegimensTherapySubtypesDiagnosis
2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda W, Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis C, Bartlett N, Byrd J, Caimi P, Fayad L, Fisher R, Glenn M, Habermann T, Harris N, Hernandez-Ilizaliturri F, Hoppe R, Horwitz S, Kaminski M, Kelsey C, Kim Y, Krivacic S, LaCasce A, Martin M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad A, Snyder E, Sokol L, Swinnen L, Vose J, Yahalom J, Dwyer M, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 293-311. PMID: 28275031, DOI: 10.6004/jnccn.2017.0030.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaTreatment of patientsNCCN Clinical Practice GuidelinesCD20 monoclonal antibodyNCCN Guidelines InsightsClinical practice guidelinesRelapsed/refractory CLL/SLLChemoimmunotherapy regimensLymphocytic lymphomaCritical signaling pathwaysLymphocytic leukemiaSmall molecule inhibitorsCLL/SLLBcl-2 familyBcl-2Monoclonal antibodiesMolecule inhibitorsSignaling pathwayPractice guidelinesPatientsNCCNTreatmentLymphomaRegimens
2016
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Daly M, Pilarski R, Berry M, Buys S, Farmer M, Friedman S, Garber J, Kauff N, Khan S, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Merajver S, Offit K, Pal T, Reiser G, Shannon K, Swisher E, Vinayak S, Voian N, Weitzel J, Wick M, Wiesner G, Dwyer M, Darlow S. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal Of The National Comprehensive Cancer Network 2016, 15: 9-20. PMID: 28040716, DOI: 10.6004/jnccn.2017.0003.Peer-Reviewed Original ResearchConceptsGenetic/Familial High-Risk AssessmentHigh-risk assessmentOvarian cancerNCCN Clinical Practice GuidelinesNCCN Guidelines InsightsClinical practice guidelinesRisk of breastHereditary cancer syndromesPenetrant genetic mutationsMost recent recommendationsRelevant new dataPractice guidelinesCancer syndromesGenetic testingBreastSyndromeRecent recommendationsGenetic mutationsCancerManagement recommendationsRisk management recommendationsGuidelinesAssessmentPatientsRecommendations